Use of Paricalcitol in stage Vd Chronic Kidney Disease patients, over the effect of inflammatory and oxidative stress parameters.
Use of Paricalcitol in stage Vd Chronic Kidney Disease patients using a permanent catheter due to haemodialysis; over the effect of inflammatory and oxidative stress parameters. This study uses paricalcitol (vitamin D) versus atorvastatin versus paricalcitol plus atorvastatin treatments.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Enrollment
31
Oral Paricalcitol. parathyroid hormone i mcg/100. 3 days per week, the same day as haemodialysis is done, during 12 weeks.
Oral Paricalcitol. parathyroid hormone i mgc/100. 3 days a week, the same day as haemodialysis, during 12 weeks. Atorvastatin: 20 mg/day oral (1 take) during 12 weeks.
Atorvastatin: 20 mg/day oral (1 take) during 12 weeks
Hospital El Bierzo. Servicio de Nefrología.
Ponferrada, (León)., Spain
Hospital de León
León, Spain
Oxidative stress and inflammative parameters in patients wiht CKD stage Vitamin D after 12 weeks of treatment
Measure parameter: IL-2
Time frame: 12 weeks of treatment wiht visits and analysis
Oxidative stress and inflammative parameters
Measure unit: IL-4
Time frame: 12 weeks of treatment
Oxidative stress and inflammative parameters in patients with CKD stage vitamin D after 12 weeks of treatment
IL-5
Time frame: 12 weeks of treatment with visits and analysis
Oxidative stress and inflammative parameters in patients with CKD stage vitamin D after 12 weeks of treatment
IL-6
Time frame: 12 weeks of treatment with visits and analysis
Oxidative stress and inflammative parameters in patients with CKD stage vitamin D after 12 weeks of treatment
IL-10
Time frame: 12 weeks of treatment with visits and analysis
Oxidative stress and inflammative parameters in patients with CKD stage vitamin D after 12 weeks of treatment
IL-13
Time frame: 12 weeks of treatment with visits and analysis
Oxidative stress and inflammative parameters in patients with CKD stage vitamin D after 12 weeks of treatment
TNF-beta
Time frame: 12 weeks of treatment with visits and analysis
Oxidative stress and inflammative parameters in patients with CKD stage vitamin D after 12 weeks of treatment
CD3
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Time frame: 12 weeks of treatment with visits and analysis
Oxidative stress and inflammative parameters in patients with CKD stage vitamin D after 12 weeks of treatment
CD4
Time frame: 12 weeks of treatment with visits and analysis
Oxidative stress and inflammative parameters in patients with CKD stage vitamin D after 12 weeks of treatment
CD8
Time frame: 12 weeks of treatment with visits and analysis
Oxidative stress and inflammative parameters in patients with CKD stage vitamin D after 12 weeks of treatment
CD19
Time frame: 12 weeks of treatment with visits and analysis
Oxidative stress and inflammative parameters in patients with CKD stage vitamin D after 12 weeks of treatment
CD25
Time frame: 12 weeks of treatment with visits and analysis
Oxidative stress and inflammative parameters in patients with CKD stage vitamin D after 12 weeks of treatment
CD56
Time frame: 12 weeks of treatment with visits and analysis
Oxidative stress and inflammative parameters in patients with CKD stage vitamin D after 12 weeks of treatment
CD69
Time frame: 12 weeks of treatment with visits and analysis
Oxidative stress and inflammative parameters in patients with CKD stage vitamin D after 12 weeks of treatment
CD95
Time frame: 12 weeks of treatment with visits and analysis
Oxidative stress and inflammative parameters in patients with CKD stage vitamin D after 12 weeks of treatment
COX-2
Time frame: 12 weeks of treatment with visits and analysis
Oxidative stress and inflammative parameters in patients with CKD stage vitamin D after 12 weeks of treatment
iNOS
Time frame: 12 weeks of treatment with visits and analysis
Oxidative stress and inflammative parameters in patients with CKD stage vitamin D after 12 weeks of treatment
PGE2
Time frame: 12 weeks of treatment with visits and analysis
Oxidative stress and inflammative parameters in patients with CKD stage vitamin D after 12 weeks of treatment
FGF-23
Time frame: 12 weeks of treatment with visits and analysis
Nutritional Parameters
Weight
Time frame: 12 weeks of treatment with visits and analysis
Erythropoietin requirements variations
Fe
Time frame: 12 weeks of treatment with visits and analysis
Assess potential benefits inflammatory markers
PTHi
Time frame: 12 weeks of treatment with visits and analysis
Nutritional Parameters
Height
Time frame: 12 weeks of treatment with visits and analysis
Nutritional Parameters
Body Mass Index (BMI)
Time frame: 12 weeks of treatment with visits and analysis
Nutritional Parameters
Abdominal circumference
Time frame: 12 weeks of treatment with visits and analysis
Nutritional Parameters
Triceps skin fold circumference
Time frame: 12 weeks of treatment with visits and analysis
Nutritional Parameters
Bioimpedance
Time frame: 12 weeks of treatment with visits and analysis
Anaemia parameters
Hemogram
Time frame: 12 weeks of treatment
Anaemia Parameters
Biochemistry
Time frame: 12 weeks of treatment
Erythropoietin requirement variations
Ferritin
Time frame: 12 weeks of treatment with visits and analysis
Erythropoietin requirement variations
Transferrin saturation index
Time frame: 12 weeks of treatment with visits and analysis
Erythropoietin requirements variations
B12
Time frame: 12 weeks of treatment with visits and analysis
Erythropoietin requirements variations
Folic Acid
Time frame: 12 weeks of treatment with visits and analysis
Assess potential benefits in inflammatory markers
Kt
Time frame: 16 weeks, the complete duration of the study